This site is for health care professionals only.
Our 4 Bold Approaches to Cancer Treatment

Scientific Presentations

Novartis Presentations at the EHA2021 Virtual Congress

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Abstract # EP670 - POSTER

Asciminib

Asciminib Responses in Ponatinib-pretreated Patients With Chronic Myeloid Leukemia

Lead author:
Alejandro Luna
View Abstract
Abstract # EP682 - POSTER

Asciminib

A Survey of Healthcare Professionals in the United Kingdom to Describe Current Pathways and Management Practices in Chronic Myeloid Leukaemia: The ADAPT CML Survey

Lead author:
Mhairi Copland
View Abstract
Abstract # PB1517 – PUBLICATION ONLY

Nilotinib

A Multicenter Real-Word Evidence Study in the Swiss Treatment Landscape of Chronic Myeloid Leukemia

Lead author:
Stefan Balabanov
View Abstract
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Abstract # S216 - ORAL

Tisagenlecleucel

First Results of DLBCL Patients Treated With CAR-T Cells and Enrolled in DESCAR-T Registry, a French Real-Life Database for CAR-T Cells in Hematologic Malignancies

Lead author:
Steven Le Gouill
View Abstract
Abstract # EP510 - POSTER

Tisagenlecleucel

Comparative Efficacy of Tisagenlecleucel (Tisa-Cel) and Lisocabtagene Maraleucel (Liso-Cel) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Lead author:
Marie Jose Kersten
View Abstract
Abstract # EP516 - PUBLICATION ONLY

Tisagenlecleucel

Safety and Efficacy of Tisagenlecleucel Plus Pembrolizumab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Analysis of the Phase Ib PORTIA Study

Lead author:
Ulrich Jaeger
View Abstract
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
ABSTRACT #S210 - ORAL

Tisagenlecleucel

Efficacy and Safety of Tisagenlecleucel in Adult Patients With Relapsed/Refractory Follicular Lymphoma: Primary Analysis of the Phase II ELARA Trial

Lead author:
Stephen J Schuster
View Abstract
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Abstract # EP1125 - POSTER

Eltrombopag

Off-label Use of Eltrombopag in Adult Patients With Immune Thrombocytopenia Before Six Months of Disease Duration in the Real-World in France. Results of the ELEXTRA Study

Lead author:
Guillaume Moulis
View Abstract
Abstract # EP1150- POSTER

Eltrombopag

Geographic Distribution of Patient and Physician ITP Treatment Preferences and Effect of Physician Caseload on Treatment Practices: Results From the ITP World Impact Survey (I-WISh)

Lead author:
Nichola Cooper
View Abstract
Abstract # S296- ORAL

Eltrombopag

Long-term Survival in Patients With Primary and Secondary Immune Thrombocytopenia - A Nationwide Population-based Cohort Study

Lead author:
Nikolaj Mannering
View Abstract
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Abstract # S161 - ORAL

Sabatolimab

Activation of Distinct Inflammatory Pathways is Driven by Genetics in MDS

Lead author:
Marie Schneider
View Abstract
Abstract # S168 - ORAL

Sabatolimab

Sabatolimab Plus Hypomethylating Agents (HMAs) in Patients (Pts) With High-/Very High-risk Myelodysplastic Syndrome (HR/vHR-MDS) and Acute Myeloid Leukemia (AML): Subgroup Analysis of a Phase I Study

Lead author:
Andrew Wei
View Abstract
Abstract # EP1172 - POSTER

Sabatolimab

The Psychosocial Impact of Haematopoietic Stem Cell Transplantation on Adult Patients With Lymphoma, Leukaemia or Myelodysplastic Syndromes – A Literature Review

Lead author:
Pauline Frank
View Abstract
Abstract # PB1625 – PUBLICATION ONLY

Sabatolimab

Treatments and Outcomes for Patients With Myelodysplastic Syndrome (MDS) by Revised International Prognostic Scoring System (IPSS-R) Scores at the Huntsman Cancer Institute

Lead author:
Connor Willis
View Abstract
Abstract # PB1743– PUBLICATION ONLY

Sabatolimab

Experiences and Support Needs of Caregivers of Patients With Higher-risk MDS: Qualitative Insights via Online Bulletin Board in the US, UK, and Canada

Lead author:
Pauline Frank
View Abstract
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Abstract # S158 - ORAL

Ruxolitinib

Impact of Ruxolitinib on Survival of Patients With Myelofibrosis in Real World – Update of ERNEST (European Registry For Myeloproliferative Neoplasms) Study

Lead author:
Paolo Guglielmelli
View Abstract
Abstract # S236 - ORAL

Ruxolitinib

Efficacy and Safety of Ruxolitinib in Patients With Steroid-Refractory Acute Graft-Vs-Host Disease After Crossover in the Phase III REACH2 Study

Lead author:
Jeff Szer
View Abstract
Abstract # EP1075- POSTER

Ruxolitinib

Add-on Parsaclisib (a Pi3kδ inhibitor) in Patients With Myelofibrosis and Suboptimal Response to Ruxolitinib: Interim Analysis From a Phase II study

Lead author:
Abdulraheem Yacoub
View Abstract
Abstract # EP1090 - POSTER

Ruxolitinib

An Epidemiological Study of the Cardiovascular Health and Thrombotic Risk Profiles of Patients With Myeloproliferative Neoplasms in Primary Care Across the United Kingdom

Lead author:
Frederick Chen
View Abstract
Abstract # EP1092 - POSTER

Ruxolitinib

Impact of Bone Marrow Fibrosis Grade on Response and Outcome in Patients With Primary Myelofibrosis Treated With Ruxolitinib: A Post-Hoc Analysis of the JUMP Study

Lead author:
Francesca Palandri
View Abstract
Abstract # EP1107 - POSTER

Ruxolitinib

Healthcare Resource Utilization in Patients With Myeloproliferative Neoplasms: A Nationwide Matched Cohort Study

Lead author:
Sarah Christensen
View Abstract
Abstract # PB1706 - PUBLICATION ONLY

Ruxolitinib

Bioequivalence of 50 mg Once-Daily Ruxolitinib Extended Release (XR) Tablets Compared to 25 mg Twice-Daily Ruxolitinib Immediate Release (IR) Tablets

Lead author:
Xiaohua Gong
View Abstract
Abstract # PB1713- PUBLICATION ONLY

Ruxolitinib

A Phase I/II Study of INCB000928 as Monotherapy or in Combination With Ruxolitinib in Patients With Anemia Due to Myelofibrosis (INCB 00928-104)

Lead author:
Stephen Oh
View Abstract
Abstract # PB1715- PUBLICATION ONLY

Ruxolitinib

A Randomized, Double-Blind, Placebo-controlled Phase III Study of Add-on Parsaclisib in Patients With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib

Lead author:
Abdulraheem Yacoub
View Abstract
Abstract # PB1716- PUBLICATION ONLY

Ruxolitinib

A Phase III, Randomized, Double-blind, Placebo-controlled Study of Ruxolitinib Plus Parsaclisib in Patients With JAK- and Pi3K-inhibitor Treatment–naïve Myelofibrosis

Lead author:
Abdulraheem Yacoub
View Abstract
Abstract # PB1717 – PUBLICATION ONLY

Ruxolitinib

Relative Bioavailability and Dose Linearity of Five Strengths of Ruxolitinib Extended Release (XR) Tablets

Lead author:
Xiaohua Gong
View Abstract
Abstract # PB1723- PUBLICATION ONLY

Ruxolitinib

ADORE: A Randomized, Open-Label, Phase I/II Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients With Myelofibrosis

Lead author:
David Ross
View Abstract
Abstract # PB1780 – PUBLICATION ONLY

Ruxolitinib

A Phase II Open-Label, Single-Arm, Multicenter Study of Ruxolitinib Added to Corticosteroids in Pediatric Subjects With Moderate and Severe Chronic GvHD After Allogeneic Stem Cell Transplantation (REACH5)

Lead author:
Cristina Diaz-de-Heredia
View Abstract
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Abstract # S173 - ORAL

LNP023

First-line Treatment of PNH Patients With Iptacopan Leads to Rapid and Durable Hemoglobin Increase by Controlling Both Intra- and Extravascular Hemolysis

Lead author:
Jun Ho Jang
View Abstract
Abstract # PB1476- PUBLICATION ONLY

LNP023

Phase III Study of Efficacy and Safety of Iptacopan (LNP023), an Oral Complement Factor B Inhibitor, in Pts with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia Despite Anti-C5 Antibody Treatment

Lead author:
Antonio M Risitano
View Abstract
Abstract # PB1481 – PUBLICATION ONLY

LNP023

Phase III Study of the Efficacy and Safety of Iptacopan (LNP023), an Oral Factor B Inhibitor, in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Naïve to Complement Inhibitor Therapy

Lead author:
Régis Peffault de Latour
View Abstract
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Abstract # S314 - ORAL

Crizanlizumab

The Burden of Sickle Cell Disease (SCD) on Patients in Ghana and Nigeria Compared With Other Low-/Middle-Income and High Income Countries: Results From the Sickle Cell World Assessment Survey (SWAY)

Lead author:
Ifeyinwa Osunkwo
View Abstract
Abstract # EP1207 - POSTER

Crizanlizumab

Association Between Hospitalised Vaso-Occlusive Crises and Mortality in Sickle Cell Disease Patients Aged 16 Years and Older Using the French National Health Insurance Database (SNDS)

Lead author:
Jean-Benoît Arlet
View Abstract
Abstract # EP1211- POSTER

Crizanlizumab

Real-world Data From the Crizanlizumab Managed Access Program (MAP): Baseline Disease Burden and Prior Treatments for Patients With Sickle Cell Disease (SCD) and Recurrent Vaso-Occlusive Crises (VOCs)

Lead author:
Ana Cristina Silva-Pinto
View Abstract
Abstract # EP1219 - POSTER

Crizanlizumab

A Longitudinal Observational Study to Evaluate the Psychometric Properties of a Daily Diary for Adolescents and Adults With Sickle Cell Disease

Lead author:
R Clark Brown
View Abstract
Abstract # EP1220 - POSTER

Crizanlizumab

Economic Burden of Sickle Cell Disease in the Middle East

Lead author:
Hatoon Ezzat
View Abstract
Abstract # EP1222 - POSTER

Crizanlizumab

Factors Associated With Hospital Admission Due To Vaso-Occlusive Crisis in Patients With Sickle Cell Disease: Retrospective Analysis of 3-Year Observational Study Data

Lead author:
Matthew M Heeney
View Abstract
Abstract # PB1762 – PUBLICATION ONLY

Crizanlizumab

Impact of Sickle Cell Disease on Daily Life in Patients Managing Vaso-Occlusive Crises at Home Vs the Emergency Room/Hospital: Results From the International Sickle Cell World Assessment Survey (SWAY)

Lead author:
Erfan Nur
View Abstract
Abstract # PB1766– PUBLICATION ONLY

Crizanlizumab

The GREATalyS (Generating Real World Evidence Across Italy in SCD): Epidemiology and Disease Burden in Italy

Lead author:
Chiara Castiglioni
View Abstract
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Aplastic Anemia

Aplastic Anemia

Abstract # S157 - ORAL

Eltrombopag

Evaluation of the Impact of the Use of Eltrombopag in a Real-life Setting in France Based on Data in the National Observatory for Medullar Insufficiency (RIME): The REVEPI Study

Lead author:
Flore Sicre de Fontbrune
View Abstract
Abstract # S172 - ORAL

Eltrombopag

An Interventional, Phase II, Single-Arm Study to Assess the Efficacy and Safety of Eltrombopag Combined with Cyclosporine as First-Line Therapy in Adults with Severe Acquired Aplastic Anemia (SOAR)

Lead author:
Efreen Montaño-Figueroa
View Abstract

Mastocytosis

Mastocytosis

Abstract # EP1095 - POSTER

Midostaurin

First Real-Life Results On Patients With Advanced Systemic Mastocytosis Treated With Midostaurin in France

Lead author:
Julien Rossignol
View Abstract